For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective

the ONA take:

According to a new study published in the Journal of Clinical Oncology, cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer. In the phase 2 study, researchers assigned patients with advanced, persistent, or recurrent cervical cancer to received either cisplatin in combination with pemetrexed or paclitaxel.

 

Researchers found that patients with no prior history of chemotherapy that received cisplatin plus pemetrexed had a 31% response rate for a duration of up to 7 months and an overall survival of 12 months. Patients that received cisplatin plus paclitaxel had a 29% response rate for a duration of up to 6 months and an overall survival of 13 months.

 

Furthermore, the pemetrexed combination was observed to be less toxic compared with the paclitaxel combination. Researchers also observed increased survival rates when adding bevacizumab to the paclitaxel combination, so researchers suggest possibly adding bevacizumab to the pemetrexed combination.

 

According to the Centers for Disease Control and Prevention (CDC), cervical cancer used to be the leading cause of cancer-related death in women in the United States, but regular Pap screenings have led to early cancer detection and decreased mortality.

For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective
Cisplatin plus pemetrexed improved response rates in patients with advanced cervical cancer.

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

The cancer-fighting cocktail, which combines the chemotherapy drug cisplatin with pemetrexed - an agent that stops cancer cells from dividing - showed promising results for advanced, persistent, or recurrent cervical cancer.

READ FULL ARTICLE From Topix
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs